Pharming Group N.V. - ADR (PHG)
XFRA 
Summary
PHG Chart
Pharming Group Q1 Earnings Call Highlights
Pharming Group NASDAQ: PHAR executives said first-quarter 2026 results reflected an expected decline in RUCONEST revenue tied largely to specialty pharmacy inventory movements and the company's planned exit from certain non-U.S. markets, while Joenja continued to post strong growth and the company advanced regulatory and clinical milestones across its pipeline. Get Pharming Group alerts:Sign UpRUCONEST revenue declined as inventory dynamics played out CEO Fabrice Chouraqui said quarterly revenue fell primarily due to RUCONEST, a decline he said was “largely expected due to inventory drawdown at specialty pharmacy,” which the company previously discussed on its fourth-quarter 2025 call.
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
Pharming Group N.V. - ADR (PHG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pharming Group N.V. - ADR ever had a stock split?
Pharming Group N.V. - ADR Profile
| Biotechnology Industry | Healthcare Sector | Fabrice Chouraqui CEO | XFRA Exchange | US71716E1055 ISIN |
| NL Country | 404 Employees | - Last Dividend | - Last Split | 23 Dec 2020 IPO Date |
Overview
Pharming Group N.V. is an established player in the field of biopharmaceuticals, focusing its efforts on the development and commercialization of innovative protein replacement therapies and precision medicines aimed at treating rare diseases. With a geographical footprint that spans the United States, Europe, and other international markets, Pharming Group has carved a niche for itself by targeting conditions that have traditionally been under-addressed by the larger pharmaceutical industry. Since its inception in 1988, the company has been headquartered in Leiden, the Netherlands. Through strategic collaborations with other pharmaceutical leaders like Novartis and Orchard Therapeutics plc, Pharming Group N.V. continues to expand its research, development, manufacturing, and commercialization capabilities, thereby solidifying its position as a key player in the rare disease treatment landscape.
Products and Services
- RUCONEST
A recombinant C1 esterase inhibitor, RUCONEST is developed to provide relief from acute attacks in adult and adolescent patients suffering from acute hereditary angioedema (HAE). The product stands as a testament to Pharming Group’s commitment to addressing the needs of individuals afflicted by this rare and potentially life-threatening genetic condition.
- Joenja (leniolisib)
This oral small molecule inhibitor specifically targets the phosphoinositide 3-kinase delta (PI3K) pathway. Joenja is designed for the treatment of activated phosphoinositide 3-kinase delta syndrome, a rare genetic disorder that affects the immune system. Its development underscores Pharming Group's dedication to advancing precision medicine for complex, rare diseases.
- OTL-105
An investigational ex-vivo autologous hematopoietic stem cell gene therapy, OTL-105 is currently under development for the treatment of HAE. This innovative approach represents the cutting edge of gene therapy, potentially offering a new paradigm in the management of hereditary angioedema. The strategic collaboration agreement with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105 evidences Pharming Group N.V.'s pioneering spirit and relentless pursuit of breakthrough treatments for rare diseases.
